Document is current
Any future updates will be listed below
-
Authors
Milani, Michela
Annoni, Andrea
Bartolaccini, Sara
Biffi, Mauro
Russo, Fabio
Di Tomaso, Tiziano
Raimondi, Andrea
Lengler, Johannes
Holmes, Michael C
Scheiflinger, Friedrich
Lombardo, Angelo
Cantore, Alessio
Naldini, Luigi https://orcid.org/0000-0002-7835-527X
-
Funding
Funding for this research was provided by:
Bioverativ
Fondazione Telethon (TGT11D03)
- License Information
-
More Information
Article History
Received: 13 June 2017
Revised: 21 July 2017
Accepted: 26 July 2017
First Online: 23 August 2017
Conflict of interest
: L.N. is inventor on patents on LV technology and microRNA‐regulated LV (gene vector, WO2007000668). A.C., A.L., and L.N. are inventors on a filed patent on MHC‐negative LV producer cells. These patents are owned by Telethon Foundation and San Raffaele Scientific Institute. The LV and reagents described in this manuscript are available to interested scientists upon signing a MTA with standard provisions. There are some restrictions concerning research involving LV for the gene therapy of hemophilia, except for research aimed at reproducing the findings reported in this manuscript, according to a collaboration agreement between Telethon Foundation, the San Raffaele Scientific Institute, and Bioverativ.
